Glenmark Pharmaceuticals South
Africa today announced the expansion of its topical dermatology portfolio with
the signing a 10-year marketing and distribution rights agreement with MeyerZall
areas covered by this distribution agreement include psoriasis, fungal infections
of the skin and inflammation with the following products now falling into the
Glenmark portfolio; Linotar Gel 1, Covarex and Athru-Derm, all with unique patented
delivery systems which are available for distribution through the South African
public health distribution network.
the addition of these products to Glenmark''s portfolio, we are now able to offer
one of the widest topical dermatology baskets in the South African market,: said
A S Mohanty, director, formulations, Glenmark Pharmaceuticals Ltd. "This
will significantly add to our existing range of Synalar, Synalar-C, Synalar-N
and Naseptin, and create a significant niche in the area of dermatology for Glenmark
in South Africa."
December 2005, Glenmark Pharmaceuticals Ltd acquired Bouwer Bartlett Pty Ltd,
a South African sales and marketing company, through Glenmark Pharmaceuticals
S,A, its wholly owned Swiss subsidiary.